Infringement Analysis in Boston.

A patent infringement analysis Boston litigators can act on has to map every asserted claim element onto a real, documented product feature — and in this region that product is as often an antibody, a surgical robot or a diagnostic assay as it is a line of software. Greater Boston is the densest life-sciences cluster in the world, with Moderna, Biogen, Vertex, Takeda and Ginkgo Bioworks anchoring Kendall Square and the Seaport, alongside a deep medtech, robotics and enterprise-software base spun out of MIT and Harvard.

A company accused of infringing a patent here is typically sued in the U.S. District Court for the District of Massachusetts, faces a parallel inter partes review at the PTAB, or defends an import action at the International Trade Commission. In each forum the case turns on a rigorous, element-by-element read of the claims against the accused product. PerspireIP builds that read for the companies fighting patents across Boston.

Where a patent infringement analysis Boston case is heard

Patent suits filed in eastern Massachusetts are heard in the U.S. District Court for the District of Massachusetts. Its Boston seat is the John Joseph Moakley U.S. Courthouse at 1 Courthouse Way on the South Boston waterfront, steps from the Seaport innovation district. Patent validity and infringement are exclusively federal questions — there is no state-court patent venue in Massachusetts, so claim construction, an infringement read and any invalidity defense all run before a federal judge.

Under the Supreme Court’s decision in TC Heartland, a company can be sued for patent infringement only where it is incorporated or where it has a regular, established place of business and has committed acts of infringement. That is why a Cambridge biotech, a Boston medtech maker or a Route 128 software company with headquarters, labs or plants in the district can properly be sued, or counter-sue, in the District of Massachusetts. Appeals do not follow the usual path: while most District of Massachusetts appeals go to the First Circuit, every patent appeal goes instead to the U.S. Court of Appeals for the Federal Circuit in Washington, D.C.

• D. Mass. (Boston) — the Moakley Courthouse, where infringement and full invalidity defenses are tried
• PTAB — inter partes review, decided nationally on novelty and obviousness over patents and printed publications
• ITC — Section 337 exclusion actions for imported devices, biologics and electronics, where non-infringement is a defense
• Federal Circuit — all patent appeals, from the district court, the PTAB and the ITC

The District of Massachusetts is one of the busier federal trial courts in the country, and its docket reflects the region’s concentration of biotech, pharmaceutical, medical-device and technology work. Judges here see patent cases regularly, so a defense built on a loose or conclusory infringement theory rarely survives. The party that arrives with a disciplined, element-by-element read of the claims controls the narrative early.

Boston’s biotech, med-device, robotics and software patent docket

Greater Boston is the world’s leading life-sciences hub, with well over 1,000 biotechnology companies clustered in Cambridge, Boston and the surrounding suburbs. Kendall Square alone is often called the most innovative square mile on the planet: Moderna, Biogen, Takeda and a dense base of RNA, gene-therapy and antibody companies sit within walking distance of MIT. Vertex and Ginkgo Bioworks anchor the Seaport and Fort Point. That concentration makes biologic, small-molecule and diagnostic claims a defining local litigation theme.

The region is far more than pharma, though. Boston is a national center for surgical robotics, medical devices, imaging and diagnostics, and for enterprise software, AI and cybersecurity spun out of MIT, Harvard, Boston University and Northeastern. A single infringement dispute here might involve an antibody sequence, a catheter or ablation device, a machine-learning model or a networking protocol — and each claim type hides its infringement proof in a different place.

• Antibody, biologic, mRNA and gene-therapy claims, often written in functional, sequence or Markush terms
• Medical-device, surgical-robotics and diagnostic-assay claims tied to physical structure and method steps
• Software, AI/ML and networking claims where the accused functionality lives in source code and system behavior
• Semiconductor and photonics claims from the region’s deep-tech and university spin-outs

Biologic and diagnostic claims in particular are non-patent-literature heavy: proving that an accused antibody or assay meets a functional claim limitation can require sequence analysis, assay data and the scientific literature, not just a product datasheet. That reality shapes how a Boston infringement read has to be built.

Local Rule 16.6 and the D. Mass. patent schedule

Unlike some districts that leave patent cases to run under general rules, the District of Massachusetts adopted a dedicated patent procedure: Local Rule 16.6, Patent Proceedings. It structures the case from the initial scheduling conference forward, forcing the parties to commit to their infringement and invalidity positions early rather than saving them for trial. For an accused infringer, that means the clock on a serious infringement and non-infringement analysis starts almost immediately.

Under Rule 16.6, the patentee must serve disclosures — including infringement claim charts mapping each asserted claim to the accused product — shortly after the scheduling conference, and the accused party responds with its non-infringement and invalidity contentions. The rule also drives the schedule toward a claim construction (Markman) hearing within roughly nine months of the initial scheduling conference and trial within about twenty-four months.

That compressed calendar rewards preparation. A defendant that already has a charted, element-by-element infringement read and a mapped non-infringement position when the scheduling conference happens can shape claim construction to its advantage, because the disputed terms it needs construed are the ones its analysis has already isolated. A defendant that waits is forced to argue construction blind.

Building claim charts and evidence of use for a patent infringement analysis Boston case

A patent infringement analysis Boston counsel can put in front of a judge starts with the claims, not the product. We construe each asserted claim, break it into its individual limitations, and then test the accused product against every limitation — because infringement requires that each and every element be met, literally or under the doctrine of equivalents. A single missing limitation defeats literal infringement, and that gap is often exactly where a defense is won.

The proof — the evidence of use — has to be real and citable. Depending on the claim, that means product teardowns and photographs, source-code review, technical datasheets and manuals, laboratory or assay data, regulatory filings, and the accused company’s own marketing and technical documentation. For a biologic or diagnostic claim we may need sequence comparisons or assay results; for a software claim, an examination of code paths and runtime behavior; for a device, a physical teardown.

• Claim construction and element-by-element mapping for every asserted claim
• Literal-infringement and doctrine-of-equivalents analysis, limitation by limitation
• Evidence of use tied to each element — teardowns, code, datasheets, assay data, regulatory records
• Non-infringement theories built around the elements the accused product does not meet
• Claim charts formatted for the Moakley courthouse, the PTAB or the ITC

The deliverable is a claim chart a District of Massachusetts judge, a PTAB panel or an ITC administrative law judge can follow line by line, backed by exhibits that survive cross-examination. Whether the goal is to prove infringement for a patent owner or to defeat it for an accused party, the discipline is the same.

IPR, district court or the ITC? Choosing the forum

A Boston company facing a patent assertion usually has more than one forum, and they are not interchangeable. Inter partes review at the PTAB is fast and cost-effective but narrow: it challenges validity only, and only on novelty and obviousness over patents and printed publications. It cannot decide infringement. Its advantage is the standard of proof — the PTAB cancels claims on a preponderance of the evidence, lower than the clear-and-convincing standard a district court applies to invalidity.

District-court litigation is where infringement is actually decided, and where the full toolkit is available: literal infringement, the doctrine of equivalents, and every invalidity and unenforceability defense, including the written-description and enablement attacks that matter so much for antibody and functional-genus claims common in Boston. A clean, well-charted non-infringement read is frequently a faster exit than an invalidity fight, because it can win on summary judgment after claim construction.

Timing drives the choice. A defendant served with a complaint must file any IPR within one year, and an IPR that reaches a final written decision carries estoppel on grounds raised or that reasonably could have been raised. Many Boston disputes therefore run parallel tracks — an infringement and non-infringement analysis for the district court alongside an invalidity search feeding the PTAB — built from one coordinated record.

The ITC, Section 337 and imported devices, biologics and electronics

Many medical devices, instruments, semiconductors and components used by Boston companies are manufactured abroad and imported into the United States, which pulls some disputes toward the International Trade Commission. Under Section 337, the ITC investigates imported goods accused of infringement and can issue an exclusion order barring them from entry — a fast, powerful remedy that can run alongside, or instead of, a district-court suit. For a company that depends on imported product, that threat is serious.

For a respondent at the Commission, a precise non-infringement analysis is a core defense, exactly as it is in district court — but on the ITC’s compressed timeline. Discovery, expert reports and the hearing before an administrative law judge all move faster than a district-court docket, so the claim charts and evidence of use have to be built and stress-tested before the schedule closes. A company that starts its infringement read at the first sign of a complaint keeps every option open, whether it is defending an import ban or asserting one.

How PerspireIP builds a patent infringement analysis Boston case

Every engagement follows the same disciplined path. We construe the asserted claims, break each one into its limitations, and test the accused product against every element for both literal infringement and the doctrine of equivalents. For biotech, medical-device and software subject-matter we pair technical teardown, source-code and sequence or assay analysis with the documentary record — datasheets, manuals, regulatory filings and the accused party’s own materials — then build claim charts a District of Massachusetts judge, a PTAB panel or an ITC administrative law judge can follow.

• Claim construction and element-by-element mapping against the accused product
• Evidence of use gathered from teardowns, code review, assay data and technical documentation
• Literal and doctrine-of-equivalents analysis, plus the strongest non-infringement theories
• Analysis sized to your forum’s deadline — the D. Mass. Rule 16.6 schedule, the PTAB’s one-year bar or the ITC’s fast track
• A written infringement or non-infringement opinion and exhibit packages ready for court, the PTAB or the Commission

We work alongside your Massachusetts litigators and patent counsel as a specialist analysis partner, deliver to court, PTAB and ITC deadlines, and keep every engagement confidential. Whether you are a biotech defending an antibody assertion, a device maker facing a mechanical or method claim, a software company accused on a functional patent, or a patent owner building an assertion, we scale to fit — a single study, a multi-patent campaign or ongoing support. Send us the patent number and the accused product, and we will scope a patent infringement analysis Boston project within one business day.

IP Landscape & Resources in Boston

Key intellectual-property authorities and venues relevant to Boston:

• U.S. District Court for the District of Massachusetts — the federal trial court in Boston (John Joseph Moakley U.S. Courthouse) that hears patent infringement and invalidity, under Local Rule 16.6
• USPTO Patent Trial and Appeal Board (PTAB) — administers inter partes review, the administrative route to challenge patent validity on prior art
• U.S. International Trade Commission — Section 337 — investigates imported devices, biologics and electronics accused of infringement and can issue exclusion orders
• U.S. Court of Appeals for the Federal Circuit — hears all appeals in patent cases, including from the District of Massachusetts, the PTAB and the ITC

Request a Patent Infringement Analysis in Boston

Explore related PerspireIP services: Patent Infringement Analysis · Patent Invalidation · Prior Art Litigation Search.

Frequently Asked Questions